Relacin, a novel antibacterial agent targeting the Stringent Response

Area of Science:

• Microbiology
• Antibiotic Discovery
• Bacterial Physiology

Background:

• Developing novel antibiotics is crucial to combat resistant bacteria.
• Identifying bacterial cellular targets is a key challenge in this endeavor.
• The bacterial enzyme RelA and the Stringent Response play vital roles in bacterial survival.

Purpose of the Study:

• To introduce a novel compound, Relacin, designed to inhibit bacterial RelA.
• To evaluate Relacin's efficacy in reducing (p)ppGpp production and impacting bacterial survival strategies.
• To explore Relacin's potential as a new antibacterial agent.

Main Methods:

• In vitro inhibition assays of RelA enzyme activity.
• In vivo studies measuring (p)ppGpp production.
• Assays assessing effects on bacterial stationary phase entry, cell viability, spore formation in Bacillus subtilis and Bacillus anthracis, and biofilm formation.

Main Results:

• Relacin demonstrated inhibition of RelA in vitro and reduced (p)ppGpp levels in vivo.
• The compound significantly affected stationary phase entry and cell viability in Gram-positive bacteria.
• Relacin markedly disrupted spore formation in Bacillus species and impeded multicellular biofilm development.

Conclusions:

• Relacin, a novel ppGpp analogue, effectively targets bacterial RelA and interferes with critical survival mechanisms.
• The compound shows promise as an attractive new antibacterial agent by disrupting bacterial long-term survival strategies.
• Relacin's impact on spore formation and biofilm disruption highlights its potential in combating pathogenic bacteria.